OBJECTIVES: Although dietary supplement use is believed to be prevalent among patients with cancer, less is known about specific associations of supplements with types of cancer. These analyses describe the use of specific supplements by 10,857 cancer survivors in comparison to cancer-free controls (n = 64,226). DESIGN: Cross-sectional cohort study. SUBJECTS/SETTINGS/LOCATION: Participants were members of the VITAL (Vitamins and Lifestyle) study, a cohort study of 75,288 men and women in western Washington State, 50-76 years of age, examining supplement use and future cancer risk. INTERVENTIONS/OUTCOME MEASURES: Respondents completed a 24-page questionnaire, including information on cancer history, demographic characteristics, and current use of vitamin, mineral, and herbal supplements. RESULTS: In this cohort, cancer survivors used similar numbers of supplements as cancer-free controls. Analyses examined the association of a diagnosis history of 11 specific cancers (n > or = 280), by anatomic site, with the high use of multivitamins and 16 individual vitamin/mineral and 20 herbal/specialty supplements. In analyses adjusted for gender, age, education, and race/ethnicity, odds ratios and 95% confidence intervals for the strongest positive associations were: cranberry pills with bladder cancer 3.44 (1.86, 6.35); zinc with ovarian cancer 2.19 (1.41, 3.40); soy with prostate cancer 1.99 (1.38, 2.87); melatonin with cervical cancer 1.86 (1.19, 2.90); and vitamin D with thyroid cancer 1.66 (1.21, 2.28). CONCLUSIONS: Future research needs to assess the efficacy and safety of these specific supplements in these specific cancer populations.
OBJECTIVES: Although dietary supplement use is believed to be prevalent among patients with cancer, less is known about specific associations of supplements with types of cancer. These analyses describe the use of specific supplements by 10,857 cancer survivors in comparison to cancer-free controls (n = 64,226). DESIGN: Cross-sectional cohort study. SUBJECTS/SETTINGS/LOCATION: Participants were members of the VITAL (Vitamins and Lifestyle) study, a cohort study of 75,288 men and women in western Washington State, 50-76 years of age, examining supplement use and future cancer risk. INTERVENTIONS/OUTCOME MEASURES: Respondents completed a 24-page questionnaire, including information on cancer history, demographic characteristics, and current use of vitamin, mineral, and herbal supplements. RESULTS: In this cohort, cancer survivors used similar numbers of supplements as cancer-free controls. Analyses examined the association of a diagnosis history of 11 specific cancers (n > or = 280), by anatomic site, with the high use of multivitamins and 16 individual vitamin/mineral and 20 herbal/specialty supplements. In analyses adjusted for gender, age, education, and race/ethnicity, odds ratios and 95% confidence intervals for the strongest positive associations were: cranberry pills with bladder cancer 3.44 (1.86, 6.35); zinc with ovarian cancer 2.19 (1.41, 3.40); soy with prostate cancer 1.99 (1.38, 2.87); melatonin with cervical cancer 1.86 (1.19, 2.90); and vitamin D with thyroid cancer 1.66 (1.21, 2.28). CONCLUSIONS: Future research needs to assess the efficacy and safety of these specific supplements in these specific cancer populations.
Authors: Nikki A Hawkins; Tenbroeck Smith; Luhua Zhao; Juan Rodriguez; Zahava Berkowitz; Kevin D Stein Journal: J Cancer Surviv Date: 2009-11-10 Impact factor: 4.442
Authors: Gabriella M John; Dawn L Hershman; Laura Falci; Zaixing Shi; Wei-Yann Tsai; Heather Greenlee Journal: J Cancer Surviv Date: 2016-02-26 Impact factor: 4.442
Authors: LeQuyen Luc; Charlotte Baumgart; Edward Weiss; Lesley Georger; Christine B Ambrosone; Gary Zirpoli; Susan E McCann Journal: Public Health Nutr Date: 2014-05-27 Impact factor: 4.022
Authors: Maarten C Bosland; Ikuko Kato; Anne Zeleniuch-Jacquotte; Joanne Schmoll; Erika Enk Rueter; Jonathan Melamed; Max Xiangtian Kong; Virgilia Macias; Andre Kajdacsy-Balla; L H Lumey; Hui Xie; Weihua Gao; Paul Walden; Herbert Lepor; Samir S Taneja; Carla Randolph; Michael J Schlicht; Hiroko Meserve-Watanabe; Ryan J Deaton; Joanne A Davies Journal: JAMA Date: 2013-07-10 Impact factor: 56.272
Authors: Katherine Van Loon; Devin Wigler; Donna Niedzwiecki; Alan P Venook; Charles Fuchs; Charles Blanke; Leonard Saltz; Richard M Goldberg; Jeffrey A Meyerhardt Journal: Clin Colorectal Cancer Date: 2013-01-12 Impact factor: 4.481
Authors: Leah M Ferrucci; Ruth McCorkle; Tenbroeck Smith; Kevin D Stein; Brenda Cartmel Journal: J Altern Complement Med Date: 2009-06 Impact factor: 2.579